HWM
NBIX icon

HB Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

HB Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
7,323
+37
+0.5% +$5.49K 0.01% 657
2026
Q1 		$960K Buy
7,286
+2,467
+51% +$327K 0.01% 682
2025
Q4 		$683K Buy
4,819
+1,249
+35% +$181K ﹤0.01% 759
2025
Q3 		$501K Buy
3,570
+1,366
+62% +$185K ﹤0.01% 854
2025
Q2 		$277K Sell
2,204
-125
-5% -$14.3K ﹤0.01% 972
2025
Q1 		$258K Sell
2,329
-406
-15% -$51.4K ﹤0.01% 1030
2024
Q4 		$373K Buy
+2,735
New +$338K ﹤0.01% 731

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HB Wealth Management's NBIX Position: Q2 2026 in Review

HB Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 0.51% in Q2 2026, buying an estimated $5.49K and bringing the position to 7,323 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #657.

HB Wealth Management first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • HB Wealth Management held 7,323 shares of Neurocrine Biosciences worth $1.23M as of Q2 2026.
  • HB Wealth Management bought 37 Neurocrine Biosciences shares in Q2 2026, an estimated $5.49K.
  • Neurocrine Biosciences made up 0.01% of HB Wealth Management's portfolio in Q2 2026, its #657 holding.
  • HB Wealth Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.